All News

Shifts in CDC Policy on COVID-19 Vaccination for Children Dilute Protection for the Vulnerable Population, ID Specialist Warns
August 19, 2025

William Schaffner, MD, ID specialist and vaccine expert, advises following state guidance on back-to-school shots and thinking through new guidance on COVID shots for kids.

Public Awareness of HPV and HPV Vaccine Remains Low, Especially in Midwest and South, Study Finds
August 19, 2025

New data shows more than one-third of US adults are unaware of HPV or the HPV vaccine, with gaps greatest in the Midwest and South, where HPV-related cancers are most common.

Viking's Oral Dual Incretin Agonist VK2735 Produces Up to 12% Weight Loss at 13 Weeks in Midstage Trial
August 19, 2025

The GLP-1/GIP receptor agonist also showed promise in an exploratory maintenance arm, producing rapid weight loss at an induction dose that was sustained after down-titration.

GLP-1 Eligibility High Among US Youth, but Insurance Gaps Limit Access: Daily Dose
August 19, 2025

Your daily dose of the clinical news you may have missed.

Vaccine Policy Shifts, Public Trust, and Countering Misinformation: A Discussion With Amesh Adalja, MD
August 18, 2025

Infectious disease expert Amesh Adalja, MD, discusses new vaccine policies, misinformation, and how PCPs can build confidence during NIAM.

The ACIP's Rich History of Debate is in Jeopardy, Not A Good Sign for Science, ID Expert Says
August 18, 2025

"The foundation of science in the new iteration of the ACIP is uncertain at best," William Schaffner, MD, observed. He is concerned about where that might lead.

Preparing for the 2025-26 Respiratory Virus Season: A Q&A With Sarah Sams, MD
August 18, 2025

Family physician Sarah Sams, MD, shares practical strategies on vaccine updates, coadministration, and addressing hesitancy this respiratory season.

Investigational Psychedelic RE104 for Postpartum Depression Delivers Positive Phase 2 Results: Reunion Neuroscience Update
August 18, 2025

In the RE104 group receiving the 30-mg dose, clinically meaningful reductions in the primary endpoint were seen on day 1 posttreatment and sustained through day 28 follow-up.

FluMist Intranasal Flu Vaccine Now Available for At-Home Delivery and Self-Administration
August 18, 2025

AstraZeneca launches FluMist Home, the first FDA-approved at-home flu vaccine service, allowing self- or caregiver administration of the intranasal influenza vaccine for the 2025–26 season.

Pharmacy-Based FIT Distribution Could Broaden CRC Screening, But Results Must be Delivered with Care, New Survey Reveals
August 18, 2025

If FIT results indicated colonoscopy, respondents preferred personal follow-up vs digital; significant barriers to undergoing fear of the test and positive cancer finding were the most significant barriers to follow-up.